穴位埋线治疗肝功能正常的慢性乙型肝炎患者早期疗效观察

Early Clinical Observation on Acupoint Catgut Embedding in Treatment of Chronic Hepatitis B with Normal Liver Function

目的:观察穴位埋线治疗肝功能正常的慢性乙型肝炎患者的早期疗效。方法:将60例肝功能正常的慢性乙型肝炎患者随机分为治疗组30例和对照组30例。治疗组取双侧肝俞和足三里穴进行穴位埋线治疗,每14 d埋线1次,3个月为1个疗程;对照组患者未给予任何治疗,仅每2周随访1次。于治疗前及治疗后每2周复查1次肝功能,治疗前后检测所有患者的HBV-DNA、IFNα,记录患者的临床症状总积分。结果:治疗后,治疗组患者的症状评分显著降低(P<0.01),较对照组症状评分亦显著降低(P<0.01);治疗组患者HBV-DNA较治疗前显著降低(P<0.01),较对照组亦有所下降(P<0.05);治疗组患者的IFNα显著升高(P<0.01),较对照组亦显著升高(P<0.01)。结论:穴位埋线治疗肝功能正常的慢性乙型肝炎患者可降低患者的病毒复制水平、促进机体生成内源性干扰素、改善患者的临床症状。

Objective： To observe the early therapeutic efficacy of acupoint catgut embedding in treating chronic hepatitis B patients with normal liver function. Methods： Sixty chronic hepatitis B patients with normal liver function were randomly divided into treatment group and control group ,with 30 cases in each group. The treatment group was treated by acupoint catgut embedding in bilateral Ganshu （BL 18 ） and Zusanli （ST 36 ） once two weeks, with a course of three months, and the contt, ol group was followed up once two weeks. The liver function, HBV-DNA, and IFNcL were tested, and the clinical symptom scores were recorded. Results ： After treatment, the symptom scores of patients in treatment group were decreased significantly compared with before treatment and control group （ P 〈 0.01 ）, the level of HBV-DNA of patients in treatment group was decreased obviously compared with before treatment and control group （ P 〈 0.01, P 〈 0.05 ）, the level of IFNa of patients in treatment group was increased markedly compared with before treatment and control group （P 〈 0.01 ）. Conclusion： Acupoint catgut embedding therapy for chronic hepatitis B patients with normal liver function can inhibit the virus replication, promote the endogenous IFN production, and improve the clinical symptoms.